

Alopecia pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

<https://marketpublishers.com/r/ABA15C65D19FEN.html>

Date: July 2020

Pages: 200

Price: US\$ 1,599.00 (Single User License)

ID: ABA15C65D19FEN

Abstracts

2020 Alopecia PIPELINE HIGHLIGHTS

Alopecia is one of the widely researched conditions during 2020 with 40 companies actively focusing on realizing pipeline's potential. Development of Alopecia medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Alopecia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Alopecia.

Good progress is anticipated during 2020 and 2021 with Alopecia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Alopecia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

Alopecia DRUG DEVELOPMENT PIPELINE OVERVIEW

The "Alopecia pipeline Research Monitor, 2020" report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Alopecia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Alopecia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Alopecia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.

Alopecia DRUG PROFILES

Alopecia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.

Phase of development

Mechanism of Action

Route of Administration

Companies involved including originator, licensing companies, developer, investors, and others

New molecular entity details

Orphan drug designation and other special status provided by regulators

Alopecia COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Alopecia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Alopecia. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 40 Alopecia companies including company overview, key snapshot, contact information, and their strategies on accelerating Alopecia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Aclaris Therapeutics Inc, Addpharma Inc, Allergan Plc, Almirall SA, Applied Biology Inc, Arcutis Inc, Arena Pharmaceuticals, Berg

LLC, BiologicsMD Inc, Bioniz Therapeutics Inc, Bioquark Inc, BirchBioMed Inc, Brickell Biotech Inc, Cassiopea SpA, Concert Pharmaceuticals Inc, Dong-A Socio Holdings Co Ltd, Eli Lilly and Co, Energenisis Biomedical Co Ltd, Exicure Inc, Follica Inc, Follicum AB, HCell Inc, Histogen Inc, Japan Tobacco Inc, JW Pharmaceutical Corp, Kintor Pharmaceutical Inc, Maxinovel Pharmaceuticals, Moogene Medi Inc, Nepsone ehf, OliX Pharmaceuticals Inc, Pfizer Inc, Phio Pharmaceuticals Corp, Quark Pharmaceuticals Inc, RiverTown Therapeutics Inc, Samson Clinical Pty Ltd, Samumed LLC, Suzhou Ribo Life Sciences Co Ltd, Suzhou Zelgen Biopharmaceutical Co Ltd, Tigo GmbH, Trittech Biopharmaceuticals Co Ltd

REASONS TO BUY

The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.

This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data

Buyers can identify most promising drug candidates for treatment of Alopecia

It allows users to strengthen their pipeline through acquisitions, licensing and collaborations

Users can estimate possible delays in the delivery of pipeline or launch of new products

Stay ahead of competition through understanding their pipeline progression, strategies and outlook

The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.

Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO ALOPECIA

- 1.1 Alopecia- Disease overview
- 1.2 Alopecia- Market Size
- 1.3 Alopecia- Companies Involved

2. ALOPECIA PIPELINE SNAPSHOT- 2020

- 2.1 Alopecia Pipeline by Phase
- 2.2 Alopecia Pipeline by Mechanism of Action
- 2.3 Alopecia Pipeline by Route of Administration
- 2.4 Alopecia Pipeline- New Molecular Entities
- 2.5 Alopecia Pipeline- Orphan Drug Designation/ Special Designation

3. ALOPECIA DRUG PROFILES

- 3.1 Current Status
- 3.2 Alopecia Drug Snapshot
- 3.3 Alopecia Therapeutic Candidates- Originator/Licensors
- 3.4 Route of Administration
- 3.5 Mechanism of Action
- 3.6 NME
- 4.1 Aclaris Therapeutics Inc Alopecia Pipeline Insights and Clinical Trials
- 4.2 Addpharma Inc Alopecia Pipeline Insights and Clinical Trials
- 4.3 Allergan Plc Alopecia Pipeline Insights and Clinical Trials
- 4.4 Amirall SA Alopecia Pipeline Insights and Clinical Trials
- 4.5 Applied Biology Inc Alopecia Pipeline Insights and Clinical Trials
- 4.6 Arcutis Inc Alopecia Pipeline Insights and Clinical Trials
- 4.7 Arena Pharmaceuticals Alopecia Pipeline Insights and Clinical Trials
- 4.8 Berg LLC Alopecia Pipeline Insights and Clinical Trials
- 4.9 BiologicsMD Inc Alopecia Pipeline Insights and Clinical Trials
- 4.10 Bioniz Therapeutics Inc Alopecia Pipeline Insights and Clinical Trials
- 4.11 Bioquark Inc Alopecia Pipeline Insights and Clinical Trials
- 4.12 BirchBioMed Inc Alopecia Pipeline Insights and Clinical Trials
- 4.13 Brickell Biotech Inc Alopecia Pipeline Insights and Clinical Trials
- 4.14 Cassiopea SpA Alopecia Pipeline Insights and Clinical Trials
- 4.15 Concert Pharmaceuticals Inc Alopecia Pipeline Insights and Clinical Trials

- 4.16 Dong-A Socio Holdings Co Ltd Alopecia Pipeline Insights and Clinical Trials
- 4.17 Eli Lilly and Co Alopecia Pipeline Insights and Clinical Trials
- 4.18 Energenesis Biomedical Co Ltd Alopecia Pipeline Insights and Clinical Trials
- 4.19 Exicure Inc Alopecia Pipeline Insights and Clinical Trials
- 4.20 Follica Inc Alopecia Pipeline Insights and Clinical Trials
- 4.21 Follicum AB Alopecia Pipeline Insights and Clinical Trials
- 4.22 HCell Inc Alopecia Pipeline Insights and Clinical Trials
- 4.23 Histogen Inc Alopecia Pipeline Insights and Clinical Trials
- 4.24 Japan Tobacco Inc Alopecia Pipeline Insights and Clinical Trials
- 4.25 JW Pharmaceutical Corp Alopecia Pipeline Insights and Clinical Trials
- 4.26 Kintor Pharmaceutical Inc Alopecia Pipeline Insights and Clinical Trials
- 4.27 Maxinovel Pharmaceuticals Alopecia Pipeline Insights and Clinical Trials
- 4.28 Moogene Medi Inc Alopecia Pipeline Insights and Clinical Trials
- 4.29 Nepson ehf Alopecia Pipeline Insights and Clinical Trials
- 4.30 OliX Pharmaceuticals Inc Alopecia Pipeline Insights and Clinical Trials
- 4.31 Pfizer Inc Alopecia Pipeline Insights and Clinical Trials
- 4.32 Phio Pharmaceuticals Corp Alopecia Pipeline Insights and Clinical Trials
- 4.33 Quark Pharmaceuticals Inc Alopecia Pipeline Insights and Clinical Trials
- 4.34 RiverTown Therapeutics Inc Alopecia Pipeline Insights and Clinical Trials
- 4.35 Samson Clinical Pty Ltd Alopecia Pipeline Insights and Clinical Trials
- 4.36 Samumed LLC Alopecia Pipeline Insights and Clinical Trials
- 4.37 Suzhou Ribo Life Sciences Co Ltd Alopecia Pipeline Insights and Clinical Trials
- 4.38 Suzhou Zelgen Biopharmaceutical Co Ltd Alopecia Pipeline Insights and Clinical Trials
- 4.39 Tigo GmbH Alopecia Pipeline Insights and Clinical Trials
- 4.40 Tritech Biopharmaceuticals Co Ltd Alopecia Pipeline Insights and Clinical Trials

5. ALOPECIA MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology

6.2 Contact Information

I would like to order

Product name: Alopecia pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

Product link: <https://marketpublishers.com/r/ABA15C65D19FEN.html>

Price: US\$ 1,599.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABA15C65D19FEN.html>